Iladatuzumab vedotin

N/A

Report date: 2024/07/12 20:00:44

Base Information

Drug NameIladatuzumab vedotin

Drug Alias NameDCDS-0780ARO-7032005

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionTubulin inhibitorsAnti-CD79B

TargetsTubulinB-cell antigen receptor complex-associated protein beta chain

Therapy Area/IndicationsLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesF. Hoffmann-La Roche Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesF. Hoffmann-La Roche Ltd

Active IndicationsN/A

Inactive IndicationsLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A